Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • SRA metadata structure

    Hello,

    We know from the SRA article in NAR that the SRA metadata model has 6 objects (http://www.oxfordjournals.org/nar/database/summary/1456)
    i. Study – high level info e.g. goals of the study, literature references – may be linked to BioProject dbase
    ii. Sample – may be linked to BioSample databases
    iii. Experiment – library information; instrument information
    iv. Run – library information; instrument information
    v. Analysis – analysis results e.g. alignments, assemblies
    vi. Submission – groups the other objects
    And that: ‘A Study consists of a series of Experiments with unique Samples. The Experiment in turn, consists of a number of Runs.’
    Our Big Question is:
    What is the object of interest – what do people refer to – is it the experiment? The study? The run? We are interested in this because we are trying to map the data flows and so which object(s) should we be following?

    We are also interested in:
    useful diagrams or descriptions the way that the metadata in the SRA is structured, including the relationships between the metadata objects
    Definitions of what a ‘run’ is.

  • #2
    It's good to see I am not the only one who gets confused with the SRA data model :-)

    I tried to think of it as a tree, but it is really a forest/graph. We use the Study accession number in publications, but then we usually only have one Experiment.

    How sure are you of the statement "A Study consists of a series of Experiments with unique Samples. The Experiment in turn, consists of a number of Runs." ?

    I do know that a Run can contain multiple Samples. This occurs when you multiplex samples into a single lane on Illumina for example. The same Sample could also be in multiple Runs, say you sequence it with Illumina and 454. And so on.

    Comment


    • #3
      The SRA submission portal is driving me over the edge. I have a massively multiplexed 454 16s pyrotag run, do I really have to create a biosample for every one of my 100+ samples??? Another question about naming objects, where does it ever end? I'm trying to put up a single run and I swear I've created a baker's dozen names for each step. There has to be a better system. I'm beginning to understand why I pull up American pubs that have their data deposited with EBI and DDBJ. Grrr!

      Comment


      • #4
        Originally posted by drdoodlebug View Post
        The SRA submission portal is driving me over the edge. I have a massively multiplexed 454 16s pyrotag run, do I really have to create a biosample for every one of my 100+ samples???
        Yes you do. But you can do it all quite easily using the "Generic.tsv" tab separated file you can create with a script or with some Excel wizardry. The online portal allows you to download it, or email sra@ncbi and they will send it to you.

        For the SRA metadata, they have a 5 sheet Excel document you can fill out for bulk submissions too. Just email sra@ncbi. They have been very helpful for our bulk (>100 sample) submissions.

        Comment


        • #5
          Thanks for the help. I'll give it a try.

          Comment

          Latest Articles

          Collapse

          • seqadmin
            Understanding Genetic Influence on Infectious Disease
            by seqadmin




            During the COVID-19 pandemic, scientists observed that while some individuals experienced severe illness when infected with SARS-CoV-2, others were barely affected. These disparities left researchers and clinicians wondering what causes the wide variations in response to viral infections and what role genetics plays.

            Jean-Laurent Casanova, M.D., Ph.D., Professor at Rockefeller University, is a leading expert in this crossover between genetics and infectious...
            09-09-2024, 10:59 AM
          • seqadmin
            Addressing Off-Target Effects in CRISPR Technologies
            by seqadmin






            The first FDA-approved CRISPR-based therapy marked the transition of therapeutic gene editing from a dream to reality1. CRISPR technologies have streamlined gene editing, and CRISPR screens have become an important approach for identifying genes involved in disease processes2. This technique introduces targeted mutations across numerous genes, enabling large-scale identification of gene functions, interactions, and pathways3. Identifying the full range...
            08-27-2024, 04:44 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by seqadmin, Today, 06:25 AM
          0 responses
          9 views
          0 likes
          Last Post seqadmin  
          Started by seqadmin, Yesterday, 01:02 PM
          0 responses
          8 views
          0 likes
          Last Post seqadmin  
          Started by seqadmin, 09-18-2024, 06:39 AM
          0 responses
          10 views
          0 likes
          Last Post seqadmin  
          Started by seqadmin, 09-11-2024, 02:44 PM
          0 responses
          13 views
          0 likes
          Last Post seqadmin  
          Working...
          X